4.6 Article

Plaque-neutralizing antibody to BA.2.12.1, BA.4 and BA.5 in individuals with three doses of BioNTech or CoronaVac vaccines, natural infection and breakthrough infection

期刊

JOURNAL OF CLINICAL VIROLOGY
卷 156, 期 -, 页码 -

出版社

ELSEVIER
DOI: 10.1016/j.jcv.2022.105273

关键词

COVID-19; SARS-CoV-2; Omicron; Neutralization; Vaccine

类别

资金

  1. Health and Medical Research Fund Commissioned Research on the Novel Coronavirus Disease (COVID-19), Hong Kong SAR [COVID1903003, COVID190126]
  2. US National Institute of Allergy and Infectious Diseases [U01-Grant AI151810, HHSN266200700005C]
  3. National Natural Science Foundation of China (NSFC)/Research Grants Council (RGC) Joint Research Scheme [N_HKU737/18]
  4. RGC theme-based research schemes [T11-712/19-N, T11-705/21-N]
  5. Guangdong-Hong Kong-Macau Joint Laboratory of Respiratory Infectious Disease [20191205]

向作者/读者索取更多资源

This study found that subvariants BA.4 and BA.5 of the Omicron variant of SARS-CoV-2 are less susceptible to neutralization by antibodies elicited by the BNT162b2 and CoronaVac vaccines. However, three doses of BNT162b2 or a booster dose of BNT162b2 following two doses of CoronaVac can elicit detectable neutralizing antibody responses to BA.4 and BA.5. Vaccinated individuals with BA.2 infections also had higher levels of neutralizing antibodies against BA.4 and BA.5 compared to vaccine-naive individuals.
Background: BA.2.12.1, BA.4 and BA.5 subvariants of SARS-CoV-2 variant-of-concern (VOC) Omicron (B.1.1.529) are spreading globally. They demonstrate higher transmissibility and immune escape. Objectives: Determine BA.2.12.1, BA.4 and BA.5 virus plaque reduction neutralization test (PRNT) antibody titres in individuals recently vaccinated with BNT162b2 (n = 20) or CoronaVac (n = 20) vaccines or those convalescent from ancestral wild-type (WT) SARS-CoV-2 (n = 20) or BA.2 infections with (n = 17) or without (n = 7) prior vaccination. Results: Relative to neutralization of the WT virus, those vaccinated with BNT162b2 had 4.8, 3.4, 4.6, 11.3 and 15.5-fold reductions of geometric mean antibody titres (GMT) to BA.1, BA.2, BA.2.12.1, BA.4 and BA.5 viruses, respectively. Similarly, those vaccinated with CoronaVac had 8.0, 7.0, 11.8, 12.0 and 12.0 fold GMT reductions and those with two doses of CoronaVac boosted by BNT162b2 had 6.1, 6.7, 6,3, 13.0 and 21.2 fold GMT reductions to these viruses, respectively. Vaccinated individuals with BA.2 breakthrough infections had higher GMT antibody levels vs. BA.4 (36.9) and BA.5 (36.9) than unvaccinated individuals with BA.2 infections (BA.4 GMT 8.2; BA.5 GMT 11.0). Conclusions: BA.4 and BA.5 subvariants were less susceptible to BNT162b2 or CoronaVac vaccine elicited antibody neutralization than subvariants BA.1, BA.2 and BA.2.12.1. Nevertheless, three doses BNT162b2 or booster of BNT162b2 following two doses of CoronaVac elicited detectable BA.4 and BA.5 neutralizing antibody responses while those vaccinated with three doses of CoronaVac largely fail to do so. BA.2 infections in vaccinated individuals led to higher levels of BA.4 or BA.5 neutralizing antibody compared to those who were vaccine-naive.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据